Our Work
Latham Represents GT Medical Technologies in Oversubscribed US$100 Million Series E Equity Financing
June 10, 2026
Firm advises the medical device company in its latest funding round to advance commercial treatment for patients with operable brain tumors.
GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, has announced the closing of an oversubscribed US$100 million Series E equity financing. The financing was led by new investor Viking Global Investors, with participation from key existing investors, including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures.
Latham & Watkins LLP advised GT Medical Technologies in the transaction with an Emerging Companies & Growth team led by Bay Area partner Luke Bergstrom, with associates Omar Ammash, Erica Kucharski, and Farah Arif.